CYCLOSERINE CAPSULES, USP
Seromycin® (Cycloserine Capsules, USP), 3-isoxazolidinone, 4-amino-, (R)- is a broad- spectrum antibiotic that is produced by a strain of
and has also been synthesized. Cycloserine is a white to off-white powder that is soluble in water and stable in alkaline solution. It is rapidly destroyed at a neutral or acid pH.
Seromycin is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, Seromycin should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent.
Seromycin may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram-negative bacteria, especially
It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of Seromycin in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.
Published Studies Related to Seromycin (Cycloserine)
Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in
patients with snake phobia: a randomized pilot study. 
CONCLUSIONS: A single administration of d-cycloserine combined with exposure
A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive
behavioral therapy outcomes in a cocaine-dependent population. 
Cocaine dependence is a chronically relapsing disorder for which its predominant
behavioral therapies are associated with only partial efficacy. The goal of this
study was to determine if the N-methyl-d-aspartate (NMDA) glutamate receptor
partial agonist and cognitive enhancer, d-cycloserine (DCS), could boost the
cocaine abstinence and treatment retention goals of cognitive behavioral therapy
Effect of D: -cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial. [2011.12]
RATIONALE: Although the effects of D: -cycloserine (DCS) and valproic acid (VPA) on the facilitation of the extinction of fear-conditioned memory have been elucidated in animals, these effects have not been clearly confirmed in humans. OBJECTIVE: This study aimed to determine the effect of DCS (100 mg) and VPA (400 mg) on the facilitation of the extinction and acquisition of fear-conditioned memory in humans... CONCLUSION: A single dose of DCS or VPA might enhance exposure-based cognitive therapy of anxiety disorders by reducing the vulnerability to reinstatement and preventing relapses of fear-conditioned responses.
A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. [2011.07]
RATIONALE: Cue-exposure therapy (CET) has been advocated as a potentially effective treatment of addictive behaviours. Strategies that enhance learning may improve the outcome of CET. D-cycloserine (DCS), a partial N-methyl-D-aspartate receptor agonist, has been shown to facilitate extinction of learned fear in rats and augment exposure-based treatment in some anxiety disorders in man. OBJECTIVE: This double-blind placebo-controlled pilot study used a cue-exposure paradigm, salient for an individual's alcohol drinking, to see if DCS would reduce cue-reactivity compared with placebo... CONCLUSION: This is the first human study to our knowledge to assess the efficacy of DCS in facilitating CET in alcohol dependence. The high proportion of subjects with little or no response to cue-exposure would make any effect of DCS very difficult to detect. It is important that future studies carefully consider the criteria for inclusion.
D-cycloserine facilitates procedural learning but not declarative learning in healthy humans: a randomized controlled trial of the effect of D-cycloserine and valproic acid on overnight properties in the performance of non-emotional memory tasks. [2011.05]
Although D-cycloserine (DCS), a partial agonist of the N-methyl-d-aspartate (NMDA) receptor, and valproic acid (VPA), a histone deacetylase inhibitor, have been investigated for their roles in the facilitation of emotional learning, the effects on non-emotional declarative and procedural learning have not been clarified...
Clinical Trials Related to Seromycin (Cycloserine)
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers [Completed]
A total of 20 subjects will participate in this four week, between groups, double-blind,
placebo controlled study. Subjects will participate in two experimental sessions separated by
approximately one week. Subjects will be randomized to receive either 50 mg cycloserine or
placebo combined with cue exposure. Several physiological and subjective outcome measures
(e. g., heart rate, blood pressure, galvanic skin response) will be obtained during the
sessions. Experimental sessions will last approximately 4. 5 hours with follow-up sessions
lasting approximately thirty minutes. Our aims are:
1. To examine the effect of cycloserine vs. placebo on extinction of smoking cue reactivity
in overnight abstinent smokers. Reactivity to smoking cues will be captured with
self-report smoking urges and physiological measures (heart rate, blood pressure, and
We hypothesize that cycloserine, relative to placebo, will facilitate extinction of
smoking cue reactivity.
2. To examine the effect of cycloserine vs. placebo when combined with two 4. 5 hour
laboratory cue exposure training sessions, on smoking behavior in smokers. Smoking
behavior will be measured with self-report smoking and saliva cotinine levels.
3. To examine the effect of cycloserine vs. placebo on memory performance in nicotine
dependent smokers. Memory performance will be measured with verbal learning, recognition
and recall tasks.
4) To examine the safety and tolerability of cycloserine treatment in smokers. We hypothesize
that cycloserine will be well tolerated by smokers.
Once Weekly D-cycloserine for Schizophrenia [Recruiting]
This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks
1, 4, & 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic
for 8 weeks in adult outpatients with schizophrenia.
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls. [Not yet recruiting]
PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life
threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U. S. adults.
One core symptom of PTSD is intense psychological distress in the presence of stimuli that
"resemble" one or more aspects of the trauma experience (DSM-IV). This phenomenon referred
to as stimulus generalization has received surprisingly little empirical testing in the
context of clinical anxiety in general, and PTSD more specifically. The current proposal
represents the first effort to study the neurobiology and pharmacology of this PTSD-relevant
learning phenomenon across those with and without PTSD. The objective of this particular
proposal is to apply fMRI and pharmacologic methods to: 1) identify brain mechanisms
associated with generalization of conditioned fear and 2) examine the pharmacologic
modifiability of levels of generalization using a partial agonist at the NMDA receptor
complex (D-cycloserine) shown to increase discrimination of CS+ (danger cue) and CS- (safety
cue) in animal studies.
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia [Recruiting]
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral
therapy can reduce impairments still present in people with stable cases of schizophrenia as
well as determine which traits make schizophrenics most likely to respond to D-cycloserine
D-cycloserine in the Management of Chronic Low Back Pain [Recruiting]
Pre-clinical studies in rats suggest that D-cycloserine (DCS) is effective in the management
of chronic neuropathic pain. This pilot study will attempt to determine the effect of
D-cycloserine in the treatment of neuropathic chronic low back pain. Other aims of this
study are to determine the safety of D-cycloserine in the treatment of neuropathic chronic
low back pain and to determine which pain measurement scales are best at measuring the
efficacy of treatment.